Literature DB >> 18762113

Metalloproteinase gene expression correlates with clinical outcome in Dupuytren's disease.

Phillip Johnston1, Debbie Larson, Ian M Clark, Adrian J Chojnowski.   

Abstract

PURPOSE: We have previously demonstrated that gene expression levels of matrix metalloproteinases (MMPs), related metalloproteinases "a disintegrin and metalloproteinase with thrombospontin motifs" (ADAMTSs), and tissue inhibitors of metalloproteinases (TIMPs) differed when comparing palmar fascia from 19 patients with Dupuytren's disease (DD) with 19 disease-free controls. We undertook to investigate whether the extent of this altered gene expression was related to clinical outcome.
METHODS: All the patients with DD were followed up for an average of 14 months from their primary fasciectomy. Clinical outcome was scored by measuring range of motion to assess total extension deficit (fixed flexion deformity [FFD] of the affected digit), total further flexion, and grip strength, and using 3 validated outcome scores: the Disability of Arm, Shoulder and Hand (DASH) questionnaire, the Michigan Hand Questionnaire (MHQ), and the Vancouver Scar Scale (VSS).
RESULTS: We found a considerable correlation between levels of gene expression of several of the MMPs (MMP2, MMP13, MMP14, MMP16, MMP 19) and ADAMTSs (ADAMTS2, ADAMTS4, ADAMTS5, ADAMTS14, ADAMTS16) and the recurrence of FFD over the follow-up period. The expression of all these genes had been shown to be increased in DD samples compared with controls. We also found that the expression levels of several of these genes correlated with 2 other preoperative measurements, total further flexion (digital roll-up) and grip strength.
CONCLUSIONS: These findings suggest that gene expression levels of key MMPs and ADAMTSs could be used to predict 1-year clinical outcome in terms of recurrent FFD of the affected finger following fasciectomy for DD. This implies that knowledge of these expression levels could be used to direct appropriate surgical and adjuvant intervention for DD. This study also provides further evidence to support the functional link between metalloproteinase gene expression and symptomatic progression or recurrence. TYPE OF STUDY/LEVEL OF EVIDENCE: Prognostic IV.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18762113     DOI: 10.1016/j.jhsa.2008.04.002

Source DB:  PubMed          Journal:  J Hand Surg Am        ISSN: 0363-5023            Impact factor:   2.230


  17 in total

1.  Update on the role of molecular factors and fibroblasts in the pathogenesis of Dupuytren's disease.

Authors:  Massimiliano Tripoli; Adriana Cordova; Francesco Moschella
Journal:  J Cell Commun Signal       Date:  2016-06-07       Impact factor: 5.782

2.  Development of a brief, 12-item version of the Michigan Hand Questionnaire.

Authors:  Jennifer F Waljee; H Myra Kim; Patricia B Burns; Kevin C Chung
Journal:  Plast Reconstr Surg       Date:  2011-07       Impact factor: 4.730

3.  Evaluation of a mitochondrial DNA mutation in maternally inherited and sporadic cases of Dupuytren disease.

Authors:  Eric R Anderson; James K Burmester; Michael D Caldwell
Journal:  Clin Med Res       Date:  2012-05-25

Review 4.  Scientific understanding and clinical management of Dupuytren disease.

Authors:  Barbara Shih; Ardeshir Bayat
Journal:  Nat Rev Rheumatol       Date:  2010-11-09       Impact factor: 20.543

5.  Molecular mechanisms and treatment strategies for Dupuytren's disease.

Authors:  David B O'Gorman; Linda Vi; Bing Siang Gan
Journal:  Ther Clin Risk Manag       Date:  2010-09-07       Impact factor: 2.423

6.  Visual Estimation of Dupuytren's Flexion Contractures-A Prospective Comparative Trial.

Authors:  Joseph P Corkum; Joshua A Gillis; David T Tang
Journal:  Plast Surg (Oakv)       Date:  2018-01-09       Impact factor: 0.947

7.  Psychometric evaluation of the Disabilities of the Arm, Shoulder and Hand (DASH) with Dupuytren's contracture: validity evidence using Rasch modeling.

Authors:  Nancy J Forget; Christina Jerosch-Herold; Lee Shepstone; Johanne Higgins
Journal:  BMC Musculoskelet Disord       Date:  2014-10-30       Impact factor: 2.362

Review 8.  Optimal functional outcome measures for assessing treatment for Dupuytren's disease: a systematic review and recommendations for future practice.

Authors:  Catherine Ball; Anna L Pratt; Jagdeep Nanchahal
Journal:  BMC Musculoskelet Disord       Date:  2013-04-10       Impact factor: 2.362

Review 9.  Metalloproteinases and their inhibitors-diagnostic and therapeutic opportunities in orthopedics.

Authors:  Björn Pasternak; Per Aspenberg
Journal:  Acta Orthop       Date:  2009-12       Impact factor: 3.717

10.  Genome-wide analysis using exon arrays demonstrates an important role for expression of extra-cellular matrix, fibrotic control and tissue remodelling genes in Dupuytren's disease.

Authors:  Helen B Forrester; Peter Temple-Smith; Seungmin Ham; David de Kretser; Graeme Southwick; Carl N Sprung
Journal:  PLoS One       Date:  2013-03-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.